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Abstract
Background: The Epidermal Growth Factor Receptor (EGFR) activated Extracellular-signal Regulated
Kinase (ERK) pathway is a critical cell signalling pathway that relays the signal for a cell to proliferate from
the plasma membrane to the nucleus. Deregulation of the EGFR/ERK pathway due to alterations affecting
the expression or function of a number of pathway components has long been associated with numerous
forms of cancer. Under normal conditions, Epidermal Growth Factor (EGF) stimulates a rapid but
transient activation of ERK as the signal is rapidly shutdown. Whereas, under cancerous mutation
conditions the ERK signal cannot be shutdown and is sustained resulting in the constitutive activation of
ERK and continual cell proliferation. In this study, we have used computational modelling techniques to
investigate what effects various cancerous alterations have on the signalling flow through the ERK pathway.
Results: We have generated a new model of the EGFR activated ERK pathway, which was verified by our
own experimental data. We then altered our model to represent various cancerous situations such as Ras,
B-Raf and EGFR mutations, as well as EGFR overexpression. Analysis of the models showed that different
cancerous situations resulted in different signalling patterns through the ERK pathway, especially when
compared to the normal EGF signal pattern. Our model predicts that cancerous EGFR mutation and
overexpression signals almost exclusively via the Rap1 pathway, predicting that this pathway is the best
target for drugs. Furthermore, our model also highlights the importance of receptor degradation in normal
and cancerous EGFR signalling, and suggests that receptor degradation is a key difference between the
signalling from the EGF and Nerve Growth Factor (NGF) receptors.
Conclusion: Our results suggest that different routes to ERK activation are being utilised in different
cancerous situations which therefore has interesting implications for drug selection strategies. We also
conducted a comparison of the critical differences between signalling from different growth factor
receptors (namely EGFR, mutated EGFR, NGF, and Insulin) with our results suggesting the difference
between the systems are large scale and can be attributed to the presence/absence of entire pathways
rather than subtle difference in individual rate constants between the systems.
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Mitogen Activated Protein Kinase (MAPK) pathways are at
the heart of molecular signalling networks that govern the
growth, proliferation, differentiation and survival of
many, if not all, cell types [1]. MAPK pathways are dereg-
ulated in various diseases ranging from cancer to immu-
nological, inflammatory and degenerative syndromes,
and thus represent increasingly important drug targets.
Perhaps the most important and intensively studied
MAPK pathway is the Extracellular-signal Regulated
Kinase (ERK) pathway, which is typically initiated by the
activation of cell surface receptors, such as the Epidermal
Growth Factor Receptor (EGFR; Figure 1). The EGFR is a
growth factor receptor that induces cell proliferation
through the binding of its ligand, Epidermal Growth Fac-
tor (EGF). The binding of EGF to the EGFR induces con-
formational changes within the receptor that increases the
catalytic activity of its intrinsic tyrosine kinase and also
promotes the dimerisation of receptors. This dimerisation
Schematic of the EGF activated ERK pathwayFigure 1
Schematic of the EGF activated ERK pathway: This is a schematic of the EGF activated ERK pathway beginning at the 
level of EGF binding to EGFR and finishing at the level of ERK; see the text for more details on the features and functions of the 
pathway. Mutations to the proteins highlighted in red are well known to result in the constitutive activation of ERK, leading to 
the subsequent development cancer.Page 2 of 17
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residues in the receptor, which act as docking sites for a
plethora of cytoplasmic adaptor proteins, typically con-
taining SH2 or PTB domains. Among these adaptor pro-
teins are Grb2 and Crk which are able to recruit the
guanine nucleotide exchange factors SOS and C3G,
respectively, to the receptor complex. This recruitment
brings SOS and C3G into close proximity to their mem-
brane bound targets, the small G-proteins Ras and Rap1,
respectively, where they can load them with GTP. Ras-GTP
and Rap1-GTP bind Raf kinases with high affinity translo-
cating them from the cytoplasm to the cell membrane
where they are activated. Active Raf proteins dual phos-
phorylate and activate MAPK/ERK kinase (MEK) which in
turn dual phosphorylates and activates ERK. Activated
ERK has over 100 targets in both the cytoplasm and
nucleus [2], including numerous transcription factors,
and can therefore directly effect gene expression and influ-
ence cellular outcome. In addition, ERK is able to phos-
phorylate SOS (via p90Rsk) which results in its
dissociation from Grb2, thus forming a negative feedback
loop within the pathway [3-7].
A common cell line used to investigate ERK signalling
from growth factor receptors is the PC12 (rat pheochro-
mocytoma) cell line. In PC12 cells, EGF stimulates a
strong but transient activation of ERK, peaking at ~5 mins
and returning to basal levels at ~30 mins, which leads to
cellular proliferation [8,9]. In contrast, Nerve Growth Fac-
tor (NGF) stimulates a sustained activation of ERK leading
to the neuronal differentiation of PC12 cells [8,9]. There
is now compelling evidence that the duration of the ERK
signal governs whether PC12 cells proliferate or withdraw
from the cell cycle and differentiate into a neuronal phe-
notype [9,10]. Although the PC12 system has been well
studied, it is still unclear how different ERK signal dynam-
ics can be robustly controlled by different upstream recep-
tors utilising the same pathway. However, there are
currently a number of theories such as differences in the
strength of feedback loops between receptor systems
[11,12] and differences in the adaptor proteins that can
bind to the receptor to initiate the ERK pathway [9].
Numerous other growth factor receptors (such as the Insu-
lin, Fibroblast, and Platelet-Derived receptors) also use
this same ERK pathway to generate different signals and
different cellular responses. Therefore, an understanding
of the critical differences between the receptor systems
and how they utilise the same pathway to generate differ-
ent responses would be a major advance.
Alterations in the cellular genome affecting the expression
or function of genes controlling cell growth are consid-
ered to be the main cause of cancer [13]. Common altera-
tions include mutations to the Ras and B-Raf proteins as
well as mutation or overexpression of the EGFR, which all
lead to the constitutive activation of ERK. Approximately
30 % of all human cancers contain a mutation to one of
the ras oncogenes (Ki-ras, Ha-ras, N-ras) that causes the
resulting protein to be constitutively active [13]. A consti-
tutively active Ras is able to continually activate Raf
kinases and therefore MEK which subsequently results in
the constitutive activation of ERK and uncontrolled cellu-
lar proliferation. Constitutively active Ras is typically
caused by mutations that prevent GTP hydrolysis, thus
locking Ras in a permanent 'on' state. One of the most
common Ras mutations is a glycine to valine mutation at
residue 12 (RasV12) which renders Ras insensitive to inac-
tivation by Ras-GAP and thus locked in the 'on' state.
Somatic missense mutations of B-Raf have been reported
in 66 % of malignant melanomas and at lower frequen-
cies in a wide range of other human cancers [14]. By far
the most common mutation is a single substitution of
glutamic acid to valine at residue 600 (B-RafV600E) which
greatly elevates the kinase activity of B-Raf and results in
the constitutive activation of ERK in vivo, independent of
Ras [14].
Mutations, deletions and overexpression resulting in con-
stitutive activation of EGFR have long been associated
with various types of cancer [15]. The most common
mutation of the EGFR found in human cancer is EGFRvIII
which has been found in more than 50 % of high and low
grade gliomas [16] and in 21 of 27 breast carcinomas
[17,18], amongst others. EGFRvIII can be caused by intra-
gene rearrangements or alternative splicing resulting in
the loss of domains I and II from the extracellular domain.
EGFRvIII has a constitutively activated tyrosine kinase
which results in the phosphorylation of receptor tyrosine
residues and the continual recruitment of adaptor pro-
teins, and subsequently the constitutive activation of ERK
and uncontrolled cellular proliferation, independent of
ligand interaction. It has also been shown that EGFRvIII is
not internalised [19], thus avoiding the receptor degrada-
tion pathway, and is often amplified resulting in overex-
pression [17,20]. Another EGFR deletion is EGFRvI which
is a total deletion of the extracellular domain resulting in
a constitutively active EGFR which resembles the v-erb-B
oncoprotein [20,21]. Gene amplification of the EGFR
gene has also been observed in a number of different
tumours and found to be present in ~40 % glioblastoma
multiforme [22]. Overexpression of EGFR was also fre-
quently observed in breast, bladder, cervix, kidney, and
ovarian tumours [23] as well as in lung cancer and various
squamous carcinomas [15]. Overexpression results in a
greatly increased number of receptors on the cell mem-
brane. This means that receptors randomly bump into
each other with high frequency enabling them to dimerise
and auto-phosphorylate in the absence of ligand and thus
leads to the constitutive activation of the ERK pathway;
although these receptors are degraded along the normalPage 3 of 17
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ished due to the overexpression.
Over recent years the computational modelling of biolog-
ical systems has become increasingly valuable and there
are now a wide variety of models of the ERK pathway
available which have led to some novel insights and inter-
esting predictions as to how this system functions [1].
Early models of the ERK pathway were focussed on inves-
tigating the properties and behaviour of the core cascade
itself. For example, [25] showed that the ERK cascade
exhibited ultrasensitivity whilst [26,27] showed that the
activating dual phosphorylation of ERK was accom-
plished via a two-collision distributive mechanism. Now-
adays, models routinely incorporate receptors and the
plethora of adaptor proteins which can bind to them and
activate the core ERK cascade. These models have been
used to investigate various aspects of the biological behav-
Schematic and simulations of original Brown et al. (2004) EGF modelFigure 2
Schematic and simulations of original Brown et al. (2004) EGF model: (A) This is a basic schematic of the original 
model of the EGF activated ERK pathway developed by [29]; activating reactions are shown with solid lines ending in arrows 
whereas deactivating reactions are shown with dashed lines ending in diamonds. We used this model to investigate the effects 
of a Ras mutation (highlighted in red) and an EGFR mutation (green), as well as the roles of the SOS (highlighted with red line) 
and Raf-1 (green) negative feedback loops. All the lines in graph (B) and (C) represent simulated active ERK levels over 60 min-
utes. (B) The blue line represents active ERK levels from the normal EGF model, whereas the green and red lines represent 
active ERK levels from the Ras and EGFR mutation models, respectively; the EGFR mutation (green line) is practically indistin-
guishable from the normal simulation (blue line) and hence the blue line is obscured from view. (C) The blue line is the same as 
in (B), whereas the green line represents active ERK levels after the Raf-1 feedback loop has been knocked out, and the red line 
represents active ERK levels after the Akt feed-forward and SOS feedback loops have been knocked out.Page 4 of 17
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[11] and receptor internalisation [28] as well as the tem-
poral dynamics of activation by different receptors
[29,30].
In this study, we have used computational modelling
techniques to investigate what effects various cancerous
alterations have on signalling through the ERK pathway.
We have generated a new model of the EGF activated ERK
pathway which was based on a previously published
model by [29] and has been verified by our own experi-
mental data. We then altered our model to represent vari-
ous cancerous situations such as Ras, B-Raf and EGFR
mutations causing constitutive activation, as well as EGFR
overexpression. Analysis of the models showed that differ-
ent cancerous situations resulted in different signalling
patterns through the ERK pathway, especially when com-
pared to the normal EGF signal pattern. Our results sug-
gest that different routes to ERK activation are being
utilised in different cancerous situations, which therefore
has interesting implications for drug selection strategies.
Furthermore, our model also highlights the importance of
receptor degradation in normal EGF signalling, and sug-
gests that receptor degradation is a key difference between
the signalling from different growth factor receptors - spe-
cifically the EGF and NGF receptors. Detailed information
on the model as well as our analysis results is presented
below.
Methods
In 2004, Brown et al. [29] developed computational mod-
els of the EGF and NGF activated ERK pathway in PC12
cells. [29] initially constructed the topological structure of
the model and then used a novel ensemble method to
automatically assign values to model parameters based on
available experimental time course data. Using this
approach, [29] generated models of the EGF and NGF
activated ERK pathway and used them to make a number
of interesting predictions; for example, that knocking out
Akt would have little effect on ERK activation. Overall, the
Brown EGF model consists of 13 different protein species
involved in 16 biochemical reactions, which primarily uti-
lise Michaelis-Menten kinetics, and considers the SOS-
Ras-Raf-1 pathway leading to ERK activation as well as the
SOS negative feedback and Akt negative feed-forward
loops (Figure 2a).
In this study, we were interested in investigating what
effects various cancerous alterations had on signalling
through the EGF activated ERK pathway. Initially, we took
the original Brown EGF model (downloaded from Bio-
Models [31]) and investigated what effects introducing a
Ras or an EGFR mutation had on ERK signalling (Figure
2a); to accomplish this, the software tool COPASI [32]
was used for the construction, simulation and analysis of
models. Under normal conditions, the original Brown
model correctly predicts that EGF stimulates the transient
activation of ERK (Figures 2b). Furthermore, when Ras is
mutated causing it to be constitutively active, the model
correctly predicts that ERK is also constitutively activated
(Figure 2b). However, when EGFR is mutated causing it to
be constitutively active, the Brown model incorrectly pre-
dicts that ERK is only transiently activated (Figure 2b).
This is certainly incorrect because, as described above,
mutations in EGFR that cause it to be constitutively active
are well known to lead to the constitutive activation of
ERK and to the subsequent development of cancer. After
brief investigations, we found that the reason for this
incorrect prediction was that the negative feedback loop
from active ERK to SOS (via p90Rsk) is very strong and
rapidly shuts down the Ras to ERK signalling pathway,
resulting in only a transient activation of ERK despite the
constitutive activation of EGFR. Deleting the SOS feed-
back loop from the model results in a sustained activation
of ERK after normal EGF stimulation which suggests that
it is the key process involved in terminating the signal
from the EGF receptor in the Brown model (Figure 2c); in
contrast, deleting the Akt to Raf-1 feed-forward loop has
little effect on the ERK signal (Figure 2c). The ERK to SOS
negative feedback loop has been well characterised [3-
7,33] and there is therefore little doubt that it does exist.
However, our results here strongly suggest that due to this
feedback loop, an alternative to the SOS-Ras-Raf-1 path-
way must exist in order for mutated EGFR to constitutively
activate ERK. In addition, making EGFR constitutively
active made little difference to the model behaviour
because, in the Normal Brown EGF model, all of the
receptors are very rapidly activated by EGF and they
remain activated because the degradation of receptors is
not taken into account. Thus, all normal EGFR are essen-
tially constitutively active after stimulation with EGF and
hence there is little difference between the normal and
EGFR mutation model simulations. This highlights the
potential importance of the process of receptor degrada-
tion, as without it normal EGFR receptors remain consti-
tutively active.
As EGFR mutations are well known to constitutively acti-
vate ERK causing cancer, we decided to generate a new
model of the EGF activated ERK pathway which would
correctly predict the effects of various cancerous altera-
tions and enable further investigations. To accomplish
this we took the original Brown EGF model [29,33] and
made a number of modifications and expansions. These
modifications were informed by the scientific literature
and in particular by the recent study by [9] which is one
of the most comprehensive and up-to-date studies of the
EGF and NGF signalling pathways in PC12 cells. In this
study, [9] reported that EGF stimulation results in the acti-
vation of both Ras (via SOS recruitment) and Rap1 (viaPage 5 of 17
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model did not include the C3G/Rap1 pathway. [9] also
reported that activated Ras is able to activate both Raf-1
and B-Raf, adding additional complexity to the pathway,
whilst activated Rap1 is only able to activate B-Raf. Fur-
thermore, [9] reported that EGFR was rapidly ubiquiti-
nated and subsequently degraded after EGF stimulation.
Therefore, we developed a new model of the EGF activated
ERK pathway by using the original Brown EGF model as a
base to develop from. Our new model consists of 17 pro-
teins involved in 31 reactions, which utilise primarily
Michaelis-Menten but also mass action kinetics, and con-
siders the production and degradation of EGFR as well as
the Ras and Rap1 pathways leading to ERK activation (Fig-
ure 3); a Systems Biology Markup Language (SBML; [34])
version of our model is available with this publication
(see Additional file 1) or at the following website: http://
www.dcs.gla.ac.uk/~rorton/cancermodel.html. We firstly
validated the behaviour of our model against our own
laboratory data of EGF stimulated ERK activation in PC12
cells and then used the model to investigate the effects of
various cancerous alterations on the ERK signalling path-
way; specifically, the effects of mutations in Ras, B-Raf and
EGFR and also the effects of EGFR overexpression.
Results and Discussion
EGFR Signalling
Firstly, we simulated our new model under normal EGF
stimulation conditions to verify that it still gave a strong
transient activation of ERK. As can be seen in Figure 4a,
ERK is rapidly activated reaching a maximum at ~5 mins
and returning to basal levels at ~30 mins. We validated the
behaviour of the model by comparing it to our own exper-
imental data of EGF stimulated ERK activation in PC12
cells and there was a good fit between the model and
experimental data (Figure 4a); please see the Additional
file 2 for a description of laboratory experiment protocols.
As can be seen, both the model and the experimental data
have similar shapes, peak at the same time point, and
return to basal levels at the same time. As there are two
pathways leading from the receptor to ERK activation,
specifically the Ras and Rap1 pathways, we investigated if
the normal EGF system was predominantly using one
pathway or using both equally. As can be seen in Figure
Schematic of new model of EGF activated ERK pathwayFigure 3
Schematic of new model of EGF activated ERK pathway: This is a schematic of our new model of the EGF activated 
ERK pathway which was developed from the original [29] EGF model. The new model considers receptor production and deg-
radation as well as the Ras and Rap1 pathways leading to the activation of ERK. We used this model to investigate the effects 
of a number of cancerous alterations such as a Ras mutation, B-Raf mutation, EGFR mutation, and EGFR overexpression; all 
these cancerous alterations are highlighted in red.Page 6 of 17
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almost equally (which conforms well with the observa-
tions of [9]), but the Ras signal is terminated quicker due
to the presence of the ERK to SOS (via P90Rsk) negative
feedback loop. The relative contribution of the Ras and
Rap1 pathways was investigated further through knockout
experiments (Figure 4d). As can be seen, knocking out
either Ras or Rap1 has similar effects on the activated ERK
curve, with both knockouts resulting in a similar lowering
of the peak ERK activation. However, knocking out Ras
results in a slightly lower peak ERK signal when compared
to the Rap1 knockout, this is probably to be expected
given that Ras can activate both Raf-1 and B-Raf whilst
Rap1 can only activate B-Raf. On the other hand, knock-
ing out Rap1 results in a signal of shorter duration when
compared to the Ras knockout, which is again to be
expected given that Rap1 remains active for longer (Figure
4b) as there is no negative feedback loop within the Rap1
pathway. This suggests that the Ras pathway primarily
contributes to the peak of the ERK signal, whilst the Rap1
pathway contributes to the peak (although less than Ras),
as well as the duration of the ERK signal. What is impor-
tant here is that the EGFR system does not appear to
favour either or the two pathways and uses both relatively
equally, this is important for comparison in the next sec-
tion when cancerous mutations are introduced.
One interesting point is that the SOS negative feedback
loop is no longer essential for efficient signal shutdown
and the transient activation of ERK, as deleting it has only
Simulation results of our new EGF activated ERK pathway modelFig re 4
Simulation results of our new EGF activated ERK pathway model: (A) ERK Plots: The blue line represents the simu-
lated levels of active ERK over 60 minutes from the model whereas the red line represents the experimentally measured levels 
of active ERK over 40 minutes from the laboratory; as the lab data is qualitative rather than quantitative, it has been rescaled 
for comparison to the simulation data. (B) Ras/Rap1 Plots: The red and blue lines represent the simulated levels of active Ras 
and active Rap1, respectively, over 60 minutes from the model. (C) Knockout Plots: All the lines on this graph represent simu-
lated active ERK levels over 60 minutes. The blue line is the same as in (A). The green line represents active ERK levels when 
the SOS negative feedback loop is knocked out, whereas the red line represents active ERK levels when receptor degradation 
is knocked out. (D) Ras/Rap1 Knockout Plots: All the lines on this graph represent simulated active ERK levels over 60 min-
utes. The blue line is the same as in (A). The green line represents active ERK levels when Ras is knocked out, whereas the red 
line represents active ERK levels when Rap1 is knocked out.Page 7 of 17
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tor degradation is now the key factor in signal termination
as deleting the process of receptor degradation results in
the sustained activation of ERK (Figure 4c). This is a deci-
sive improvement over the original Brown EGF model,
where the SOS negative feedback loop was found to be
essential for signal termination and the transient response
(Figure 2c), as receptor degradation was not considered.
In our model, receptor degradation is now essential
because there is no negative feedback loop present on the
C3G/Rap1/B-Raf pathway so the signal has to be shut-
down at the receptor level to achieve a transient response,
which makes the process of receptor degradation essen-
tial. This has interesting and important implications for
signalling from other growth factor receptors which are
discussed further in the next section.
A sensitivity analysis of the EGFR model was also per-
formed to identify the reactions that have the most influ-
ence on the ERK signal (see Additional file 2, Figure S6;
and see Additional file 3 for model parameter values and
sources). Overall, reactions contained within the Rap1
pathway were found to be more sensitive than the corre-
sponding reactions in the Ras pathway. This is to be
expected given that the Ras pathway is contained within a
strong negative feedback loop, thus reducing the sensitiv-
ities of the reactions contained within the loop. However,
although less sensitive, the Ras pathway is still a key fea-
ture of the EGFR system. This is illustrated in the knockout
plots in Figure 4d, as knocking out Ras has a greater effect
on the peak of the ERK signal than knocking out Rap1.
This again highlights the fact that the normal EGFR system
utilises both of the pathways to relay its signal. The sensi-
tivity analysis also highlighted EGF receptor degradation
as one of the most sensitive reactions in the model. This
further highlights the importance of the process of recep-
tor degradation in addition to the knockout experiments
in Figure 4c.
Cancerous Mutations
Initially, we were interested in investigating what effects
introducing various cancerous alterations had on signal-
ling through the ERK pathway. Therefore, we introduced a
mutated constitutively active Ras into the model and ana-
lysed its effects. In the absence of EGF, the mutated Ras
resulted in the constitutive activation of ERK (Figure 5a),
as expected. This is because a constitutively active Ras,
which cannot be deactivated by Ras-GAP, is always able to
activate Raf-1 and B-Raf which results in the constitutive
activation of MEK and subsequently ERK to high levels.
Due to the presence of the PI3K -> Akt -> Raf-1 feed-for-
ward loop which deactivates Raf-1, the mutated Ras
appears to signal predominately via B-Raf (Figure 5b).
However, although a large proportion of the Raf-1 is deac-
tivated via the PI3K/Akt pathway, active Raf-1 levels still
remain high enough to fully activate ERK on its own if B-
Raf were not present (see Additional file 2, Figure S3); this
is because the Raf-1 feed-forward loop is relatively weak,
especially when compared to the SOS feedback loop (Fig-
ure 2c). These results therefore suggest that drugs that tar-
Simulation results from Ras and B-Raf mutation modelsFig re 5
Simulation results from Ras and B-Raf mutation models: (A) Ras and B-Raf Mutations: The red and blue lines represent 
the simulated levels of active ERK over 60 minutes with a B-Raf and Ras mutation, respectively; as both lines are so similar, the 
red line obscures the blue line from view for the most part. As can be seen, both Ras and B-Raf mutations result in the consti-
tutive activation of ERK to very high levels, as expected. (B) Raf Plots: Both the lines on this graph come from the Ras mutation 
model. The red and blue lines represent the simulated levels of active Raf-1 and B-Raf, respectively. As can be seen, the Ras 
mutation results in the sustained activation of B-Raf to very high levels, but the activation of Raf-1 is more transient and begins 
to decline due to the Ras/PI3K/Akt feed-forward loop.Page 8 of 17
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treating cancers caused by Ras mutation, whilst a drug (or
combination of drugs) that can target both Raf isoforms
will be much more effective. As expected, introducing a
mutated constitutively active B-Raf into the model also
resulted in the constitutive activation of ERK (Figure 5a).
This is because a constitutively active B-Raf cannot be
deactivated by its phosphatase and there is no negative
feedback loop within the B-Raf/MEK/ERK module to ter-
minate or hinder the signal. These results could not have
been obtained from the original Brown EGF model as B-
Raf and the link between Ras and B-Raf was not consid-
ered.
Our most interesting result came from introducing a
mutated constitutively active EGFR into the model.
Mutated, constitutively active, EGFR are able to activate
both SOS and C3G in the absence of EGF. As the mutated
EGFR does not bind EGF, it is not recognised as an active
receptor by the cellular machinery and is therefore not
degraded along the activated receptor degradation path-
way [15,19,35]. However, there is natural degradation/
turnover of unbound receptors (whether they are normal
or mutated) which is represented in the model, but this is
balanced out by the natural production of receptors, thus
keeping a constant level of receptors on the membrane.
Introducing the mutated EGFR into the model resulted in
the constitutive activation of ERK, in the absence of EGF
(Figure 6a), as expected; this is in direct contrast to the
original Brown EGF model which incorrectly predicted
that introducing a constitutively activated EGFR would
have no effect on the transient ERK signal (Figure 2b).
However, what is interesting is that mutated EGFR recep-
tors appear to signal almost exclusively via the C3G/Rap1/
B-Raf pathway. This can be effectively illustrated by
knockout experiments, as knocking out Ras or Raf-1 has
little effect on active ERK levels (Figure 6a) whereas
knocking out Rap1 or B-Raf has a dramatic effect and
reduces active ERK levels to almost basal levels (Figures
6b). This is in direct contrast to the pattern of signalling
observed with normal activated EGFR receptors which sig-
nal equally through both the Ras and Rap1 pathways (Fig-
ure 4b). Further investigations showed that this was again
due to the presence of the ERK to SOS (via P90Rsk) nega-
tive feedback loop which rapidly disables the Ras path-
way, whereas there is no feedback loop within the Rap1
pathway which leaves it free to be utilised by mutated
EGFR. Therefore, this implies that in cancerous situations
of EGFR mutation, drugs should target the C3G/Rap1/B-
Raf pathway in order to effectively treat such cancers; fur-
thermore, it also implies that drugs which target the SOS/
Ras/Raf-1 pathway will be ineffective treatments.
To the best of our knowledge, our model prediction that
the Rap1 pathway is the key pathway involved in signal
transduction under EGFR mutation has not been reported
previously. Indeed, it is the Ras pathway that has long
been viewed as the critical pathway in EGFR signalling [9].
However, our model predicts that although the Ras path-
way is indeed important for normal EGFR signalling, it is
Simulation results from EGFR mutation modelFig re 6
Simulation results from EGFR mutation model: All the lines in these graphs represent simulated active ERK levels over 
600 minutes. (A) Ras and Raf-1 Knockouts: The blue line represents active ERK levels with an EGFR mutation, whereas, the 
red and green lines represent active ERK levels with an EGFR mutation but also with a Ras or Raf-1 knockout, respectively; the 
green line is practically identical to the blue line and hence obscures the blue line from view. (B) Rap1 and B-Raf Knockouts: 
The blue line is the same as in (A), whereas, the red and green lines represent active ERK levels with an EGFR mutation but 
also with a Rap1 or B-Raf knockout, respectively.Page 9 of 17
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mutation. To validate our model prediction, we searched
through the scientific literature to try and find evidence of
Rap1 activity in human cancers. We first found a paper by
[36] who reported high levels of Rap1 activity in human
metastatic melanomas and cutaneous metastatic
melanoma tissues; increased ERK activity was also found
in these tumours which interestingly harboured neither B-
Raf nor Ras mutations. We subsequently found a recent
study by [37] who investigated oncogenic signalling
through the Rap1 pathway in human papillary thyroid
carcinoma (PTC). PTCs feature chromosomal aberrations
that result in the in-frame fusion of the intracellular
kinase domain of the RET receptor with the NH2 terminus
of heterologous proteins, generating the RET/PTC onco-
proteins. If the RET receptor is fused with a protein partner
that possesses a protein-protein interaction motif then it
provides the RET/PTC kinases with a dimerising interface,
thereby resulting in ligand-independent dimerisation,
auto-phosphorylation and signalling; RET/PTC1 (the H4-
RET fusion) and RET/PTC3 (the NCOA4-RET fusion) are
the most prevalent variants. [37] firstly found high levels
of Rap1 activation in human PTC cell lines which endog-
enously expressed RET/PTC1; these cells represent natural
cancerous cells rather than artificially created cancerous
cells generated through overexpression experiments. Sec-
ondly, [37] showed that a RET/PTC1-Gab1-Crk-C3G com-
plex (i.e. the Rap1 pathway) was stably present in these
cell lines. Thirdly, using si-RNA techniques, [37] were able
to knock down Gab1 expression which resulted in the
suppression of both Rap1 and ERK activation (Figure 7).
It is important to note that knocking down Gab1 would
have had no detrimental effect on the Ras pathway which
signals via SOS; in actual fact knocking down Gab1
should have a positive effect on the Ras pathway as Gab1
and SOS can compete for binding to Grb2 (Figure 7). In
essence, [37] showed that it is the Rap1 pathway that is
the critical pathway involved in PTC cancerous signalling
and that when the Rap1 pathway is knocked out (whilst
leaving the Ras pathway intact), ERK activity is abolished.
Therefore, this firmly supports our model prediction that
it is the Rap1 pathway that is the key pathway involved in
signal transduction under a cancerous receptor mutation.
It is important to note that although the study by [37] was
concerned with the RET (which plays a critical role in
renal development) rather than the EGF receptor, the two
receptors are very similar as they are both ligand induced,
transmembrane receptor tyrosine kinases which can bind
the same variety of adaptor proteins leading to the activa-
tion of both Ras and Rap1 and subsequently to ERK acti-
Experimental results of Rap1 pathway knockout from Falco et al. (2007) [37]Figu e 7
Experimental results of Rap1 pathway knockout from Falco et al. (2007) [37]: On the left, is a schematic of the 
mutated RET/PTC1 pathway as presented in [37]. On the right, is a table containing a summary of the results from the Gab1 
knock down experiment using si-RNA in two different human PTC cell lines (BHP 10-3 and BHP 2-7) from [37] (please refer to 
Figure 5c in [37] for original blots); pMEK and pERK represent the activated phosphorylated forms of MEK and ERK, respec-
tively, whilst Rap1GTP represents the activated GTP loaded form of Rap1.Page 10 of 17
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oncoproteins when mutations/deletions/fusions result in
constitutively activated receptors that are capable of con-
stitutively activating ERK. Therefore, we firmly believe that
the findings by [37] regarding the RET receptor system are
applicable to the EGFR system.
Our final model alteration was to investigate the effects of
overexpressing the EGFR which is also a known cause of
cancer. To accomplish this, the rate of receptor production
was increased 100 fold to represent the increased tran-
scription and translation of receptors. Rather than directly
representing random receptor dimerisation, we simply
stimulated the overexpressed receptors with EGF and ana-
lysed the differences between the normal and overex-
pressed systems; this is akin to the experimental strategy
employed by [10] who ovexpressed EGFR in PC12 cells
and subsequently stimulated them with EGF to investigate
the effects of overexpression. The results from this experi-
ment were extremely similar to those obtained in the
EGFR mutation experiment, and therefore the simulation
plots have been moved to Additional file 2 (Figure S4) as
they are almost identical to the plots in Figure 6a and 6b.
The overexpressed system resulted in the constitutive acti-
vation of ERK because the increased rate of receptor pro-
duction counteracted the activated receptor degradation
pathway, which resulted in a stable level of activated
receptors on the cell membrane and the constitutive acti-
vation of the ERK pathway. Similar to the mutated EGFR
receptors, the overexpressed receptors signalled predomi-
nantly via the C3G/Rap1/B-Raf as knocking out Ras or
Raf-1 had little effect on the constitutive activation of ERK,
whereas knocking out Rap1 of B-Raf had dramatic effects
with active ERK levels falling to almost basal levels. Again,
this was found to be due to the ERK to SOS (via P90Rsk)
negative feedback loop shutting down the Ras pathway,
and therefore implies that in cancerous situations of EGFR
overexpression as well as EGFR mutation, drugs should
target the Rap1 rather than Ras pathway.
Our models predict that the oncogenic EGFR signal passes
almost exclusively via the Rap1 pathway and therefore
predicts that drugs must target this pathway in order to
effectively treat such cancers. Furthermore, our models
predict that the key factor in oncogenic EGFR signalling is
the ability to bypass or compensate for receptor degrada-
tion. When the receptor is overexpressed, activated recep-
tors are still degraded but they are being constantly
replenished due to the overexpression which means that
there is a consistently high number of activated receptors
on the membrane capable of constitutively activating the
Rap1 pathway and therefore ERK. Whereas, mutated
EGFR are not recognised as being active by the normal cel-
lular machinery and are therefore not degraded which
means that they too can constitutively activate the Rap1
pathway and ERK. Therefore, our model suggests that a
drug capable of increasing the rate of EGFR degradation or
capable of somehow tagging mutated EGFRs for degrada-
tion could also be a useful developments in cancer treat-
ment.
Comparison of Growth Factor Signalling
As described previously, our normal EGF model predicts
that receptor degradation is the key process involved in
signal termination and achieving only a transient activa-
tion of ERK after EGF stimulation; if the process of recep-
tor degradation is deleted from the EGF model, a
sustained ERK signal is observed (Figure 4c) and the sen-
sitivity analysis identified it as one of the most sensitive
reactions (see Additional file 2, Figure S6). This in itself is
a novel prediction from our model, which to the best of
our knowledge has not been reported previously. Indeed,
most existing computational models of the EGF activated
ERK pathway, including the original Brown model, do not
include receptor degradation [11,29,38] or predict that it
is not necessary for signal termination [28,33]. However,
this also has wider implications with respect to ERK sig-
nalling from different growth factor receptors, and in par-
ticular could explain the differences between EGF and
NGF signalling. In PC12 cells, EGF stimulates a transient
activation of ERK whereas NGF stimulates a sustained
activation of ERK, but it is still currently unclear how these
different ERK signal dynamics can be robustly controlled
by different upstream receptors utilising the same path-
way. One of the known differences between the EGF and
the NGF receptor systems is that whilst the EGFR is rapidly
degraded, the NGF receptor TrkA is not degraded and
remains active [9]. Our model predicts that it is this differ-
ence in receptor degradation that is the key difference
between the two receptor systems. This can be investi-
gated further by deleting the process of receptor degrada-
tion from our EGF model to generate a realistic model of
the NGF receptor TrkA system.
Another receptor that utilises the ERK pathway to relay its
signal is the Insulin receptor. What is interesting about the
Insulin receptor is that it shares properties with both the
EGF and NGF receptor systems. Like the EGF receptor, the
Insulin receptor generates a transient activation of ERK;
EGF stimulates cells to proliferate whereas insulin prima-
rily has metabolic effects. However, unlike the EGF recep-
tor, the Insulin receptor is not degraded as it is efficiently
recycled back to the plasma membrane. This would
appear to contradict our previous prediction that receptor
degradation is the key to achieving a transient response,
and leads to the question as to how the Insulin receptor
can generate only a transient ERK response without the
process of receptor degradation. However, one explana-
tion for this could be that the Insulin receptor system is
not able to utilise the Rap1 pathway [4,33]. To investigatePage 11 of 17
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Comparison of growth factor receptor signallingFigure 8
Comparison of growth factor receptor signalling: This figure shows a comparison of ERK signalling from the EGF and 
Insulin receptors. At the top, a schematic of the EGF induced ERK pathway is shown in (A), with receptor degradation high-
lighted in red as it is the key process in generating a transient response, this is demonstrated in (B). All the lines in (B) repre-
sent simulated active ERK levels over 60 minutes. The blue line represents active ERK levels from the normal EGF model, the 
green line represents active ERK levels when the SOS negative feedback loop is knocked out, whereas the red line represents 
active ERK levels when receptor degradation is knocked out. At the bottom, a schematic of the Insulin induced ERK pathway is 
shown in (C), with the SOS feedback loop highlighted in red as it is the key process in generating a transient response, this is 
demonstrated in (D). All the lines in (D) represent simulated active ERK levels over 60 minutes. The blue line represents active 
ERK levels from the normal Insulin model, whilst the green line represents active ERK levels when the SOS negative feedback 
loop is knocked out. It should be noted that although not shown, both the EGF and Insulin receptor models do include the 
PI3K-Akt pathway.
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Comparison of growth factor receptor signalling continuedFigure 9
Comparison of growth factor receptor signalling continued: This figure shows a comparison of ERK signalling from the 
NGF and mutated EGF receptors. At the top, a schematic of the NGF induced ERK pathway is shown in (A), with the Rap1 
pathway highlighted in red as it is the key process in generating a sustained response, this is demonstrated in (B). All the lines 
in (B) represent simulated active ERK levels over 60 minutes. The blue line represents active ERK levels from the normal NGF 
model, the green line represents active ERK levels after the SOS negative feedback loop is knocked out, whereas the red line 
represents active ERK levels after the Rap1 pathway is knocked out. Almost identical simulation results are found for the 
mutated EGFR model (C, D), where the Rap1 pathway is again found to be the key process in generating a sustained signal due 
to the lack of receptor degradation. It should be noted that although not shown, both the NGF and mutated EGF receptor 
models do include the PI3K-Akt pathway.
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Insulin receptor system by deleting both receptor degrada-
tion and the Rap1 pathway from the EGF model. There-
fore, we now have 3 models of 3 different receptor systems
(EGF, NGF, Insulin) to directly compare and contrast, as
well as the models of the cancerous EGFR system (Figures
8, 9).
As can be seen in Figures 8, the process of receptor degra-
dation is essential to achieve a transient response in the
EGFR system whilst the SOS feedback loop is redundant,
as removing it has little effect on the transient ERK signal
dynamics (Figure 8A, B). In contrast, the SOS feedback
loop is essential to achieve a transient response in the
Insulin system (Figure 8C, D). This is because Insulin
receptors are not degraded, therefore the only way to
achieve a transient signal is via the SOS feedback loop to
shutdown the Ras pathway. Another key to the transient
signal achieved via Insulin stimulation, is the fact that the
Insulin receptor is unable to utilise the Rap1 pathway,
which does not contain a feedback loop. If the Insulin
receptor were able to utilise this pathway a sustained sig-
nal would surely be observed. Indeed, as can be seen for
the NGF receptor TrkA a sustained ERK signal is indeed
observed as the TrkA receptor is not degraded and is able
to utilise the Rap1 pathway (Figure 9A, B). One interesting
point, is that the NGF receptor system is in fact very simi-
lar to the mutated EGFR system as both systems contain
receptors that are not degraded, both can utilise the Ras
and Rap1 pathways, and both result in a sustained ERK
signal (Figure 9C, D). As discussed previously, the key to
cancerous signalling from the EGF receptor is the ability to
bypass or compensate for the process of receptor degrada-
tion. In the case of overexpressed EGFR, the process of
receptor degradation is compensated for by the increased
rate of production of new EGF receptors. Combining all of
the above leads to the prediction that, if the only real dif-
ference between EGF and NGF receptors is indeed recep-
tor degradation, a PC12 cell that is stimulated with EGF
and has overexpressed EGFR should result in a sustained
ERK signal and neuronal differentiation, not cellular pro-
liferation. Interestingly, this prediction from our model
has already been validated in a seminal experimental by
[10] who overexpressed EGFR in PC12 cells and observed
sustained ERK as well as neuronal differentiation. There-
fore, this further backs up our models and predictions
about receptor degradation being a critical process and a
key difference between the receptor systems.
In summary, the critical difference between the EGF and
the NGF systems is receptor degradation, with the EGF
receptor being rapidly degraded after stimulation and
therefore only generating a transient ERK signal, whilst
the NGF receptor TrkA is not degraded and generates a
sustained ERK signal. Whereas, the critical difference
between the Insulin and the NGF systems (both of which
are not degraded) is the Rap1 pathway, with the NGF
receptor TrkA being able to utilise it to generate a sus-
tained ERK signal, whilst the Insulin receptor is unable to
utilise it and can only use the Ras pathway which is rap-
idly shutdown via the SOS feedback loop and therefore
only generate a transient ERK signal. As the insulin recep-
tor is not degraded, this makes the SOS feedback loop
essential for signal termination and generating only a
transient ERK signal [4]. Whereas, as the EGF receptor is
degraded, the SOS feedback loop is redundant under EGF
signalling and not required for signal termination. Over-
all, our results suggest that the ERK pathway has evolved
to be utilised by numerous upstream receptors and that
the differences between ERK signalling from different
growth factor receptors seem to be large scale, with entire
processes (such as receptor degradation) or entire path-
ways (such as the Rap1 pathway) being either present or
absent, rather than subtle differences in the kinetics of
protein binding or activation.
In our previous work, we already showed through model-
ling and experimental validation that the SOS feedback
loop was not required for efficient signal termination and
the transient activation of ERK induced by EGF [33]. How-
ever, as we did not consider the Rap1 pathway in this
model, we incorrectly hypothesised that receptor degrada-
tion could also be redundant as the SOS feedback loop
could compensate for its absence. We drew parallels to the
Insulin receptor system which lacked receptor degrada-
tion, and where the SOS feedback loop had previously
been shown experimentally to be essential for signal ter-
mination and generating a transient ERK response [4,33].
Although the work presented here does not affect our pre-
vious conclusions, it does take our previous work another
step forward by considering the Rap1 pathway to show
that although the SOS feedback loop is indeed redundant,
the process of receptor degradation is actually essential in
EGF signalling. This highlights the fact that models, like
our biological understanding of the pathway itself, can
evolve over time and be used to suggest interesting new
hypotheses and explanations for the observed data that
challenge our current understanding.
Conclusion
In this study, we used computational modelling tech-
niques to investigate what effects various cancerous alter-
ations had on signalling through the EGF activated ERK
pathway. We initially introduced a number of cancerous
mutations into the original EGF model developed by [29]
but found that the model incorrectly predicted the effects
of an EGFR mutation due to the fact that the model was
incomplete (Figure 2b). We therefore constructed a new
model of the EGF activated ERK pathway by taking the
original Brown EGF model and expanding it to include
receptor production and degradation as well as the C3G/
Rap1/B-Raf pathway, which we believed were importantPage 14 of 17
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This model expansion was informed by the scientific liter-
ature, and in particular the study by [9] which is one of the
most comprehensive and up-to-date studies of the EGF
and NGF activated ERK pathway. We used our new model
to investigate the effects of cancerous mutations and what
the best drug targets would be, as well as using the model
to conduct a comparison of different growth factor recep-
tors, and as a result we have generated a number of inter-
esting and novel predictions.
Our model predicts that the oncogenic EGFR signal passes
almost exclusively via the Rap1 pathway and therefore
predicts that drugs must target this pathway in order to
effectively treat such cancers. Furthermore, our models
predict that the key factor in oncogenic EGFR signalling is
the ability to bypass or compensate for receptor degrada-
tion. When the receptor is overexpressed, activated recep-
tors are still degraded but they are being constantly
replenished due to the overexpression which means that
there is a consistently high number of activated receptors
on the membrane capable of constitutively activating the
Rap1 pathway and therefore ERK. Whereas, mutated
EGFR are not recognised as being active by the normal cel-
lular machinery and are therefore not degraded which
means that they too can constitutively activate the Rap1
pathway and ERK. Therefore, our model suggests that a
drug capable of increasing the rate of EGFR degradation or
capable of somehow tagging mutated EGFRs for degrada-
tion could be a useful developments in cancer treatment.
Our model predicts that normal EGFR signalling results in
a transient ERK signal due to receptor degradation, NGF
signalling results in a sustained ERK signal (via the Rap1
pathway) as there is no degradation of the TrkA receptor,
and cancerous EGFR signalling results in a constitutive/
sustained ERK signal (via the Rap1 pathway) because
receptor degradation is either abolished or counteracted
(Figure 8). Overall, this highlights the importance of the
Rap1 pathway in both normal and oncogenic EGFR sig-
nalling as well as in NGF signalling. The key feature of the
Rap1 pathway is that it lacks a negative feedback loop, and
will therefore keep signalling if the receptor remains
active; however, it should be noted that although there is
no negative feedback loop currently known, one can never
rule out the possibility of one being identified in the
future. Furthremore, our models predict that the key dif-
ference between the EGF and NGF receptor systems is
receptor degradation. The behaviour of these two receptor
systems in PC12 cells has long fascinated many research-
ers and our simple prediction appears to be both novel
and effectively explain how the two receptor systems are
able to utilise the same pathway to achieve different cellu-
lar responses. Interestingly, the ERK to SOS (via P90Rsk)
negative feedback loop appears to be irrelevant in both
EGF and NGF signalling, therefore one may wonder why
the SOS feedback loop is even there. However, the SOS
feedback loop is essential for a transient ERK response to
be achieved in systems such as the insulin receptor, which
are not degraded and can not utilise the Rap1 pathway
(Figure 8). Overall, our results suggest that the ERK path-
way has evolved to be utilised by numerous upstream
receptors and that the differences between ERK signalling
from different growth factor receptors seem to be large
scale, with entire processes (such as receptor degradation)
or entire pathways (such as the Rap1 pathway) being
either present or absent, rather than subtle differences in
the kinetics of protein binding or activation. Therefore, as
the differences between receptor systems are essentially
structural, this could suggest that more qualitative model-
ling techniques such as Petri-Nets [39,40] or logical proc-
ess algebras [41,42], which are more traditional tools for
analysing model structure, could play important roles in
the analysis and comparison of signal transduction path-
ways. Furthermore, as the different growth factor receptor
systems appear to be so similar, this suggests that a model
of one growth factor receptor systems could be readily
applied to another receptor system with relatively simple
modifications. Indeed, in this study we created a model of
the NGF receptor based on the EGF receptor model as well
as drawing comparisons to the RET receptor, and previ-
ously we created a model of the insulin receptor based on
a model of the EGF receptor [33]. However, the ERK path-
way is not the only pathway initiated by growth factor
receptors and as different receptors eventually lead to dif-
ferent biological responses, models will need to evolve in
the future to include these alternative adaptor proteins
and pathways, and ultimately their influence on gene
expression.
A recent study by [12] suggested that a critical difference
between the EGF and NGF systems was that a negative
feedback loop existed between Raf-1 and ERK under EGF,
but under NGF this was transformed into a positive feed-
back loop resulting in the sustained activation of ERK via
Raf-1. However, studies by [9,43], which we have used to
inform our model, showed that the sustained ERK signal
from NGF stimulation is a result of Rap1/B-Raf activity,
and that Ras/Raf-1 is only used transiently under NGF.
The EGF vs NGF phenomenon in PC12 cells has long fas-
cinated many researchers and has been well studied, but it
is still unclear exactly how different ERK signal dynamics
can be robustly controlled by different upstream receptors
utilising the same pathway, especially given such differing
data. It is important to note here, that we are not implying
that our model and the data we have used should be
trusted more than any others. Rather we are implying that
our model offers an interesting and alternative explana-
tion for the observed data, we have been able to expand
our model out from the traditional EGF vs NGF system to
incorporate cancerous mutations as well as other growth
factor receptors, and importantly we have made a numberPage 15 of 17
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idate through existing experimental results in the scien-
tific literature. Only time and further laboratory data can
tell which models and hypotheses are truly correct, if any,
but it is important to remember that all models are sim-
plifications of the true real-life situation, and therefore
any predictions from them should be treated with some
caution. In the words of George E. P. Box, "Essentially, all
models are wrong, but some are useful" [44].
In conclusion, this study has shown how computational
models can be useful tools for investigating and compar-
ing the biological behaviour of signal transduction path-
ways as they can suggest new hypotheses to explain the
observed biological data and help understand the dynam-
ics of how the pathway functions. Furthermore, computa-
tional models can be readily used to investigate different
disease states and suggest how drug treatment could be
improved to better combat the effects of the disease. Ulti-
mately, the behaviour of computational models needs to
be validated with experimental data from the laboratory
so that any predictions made from them can be trusted.
Therefore, we have validated the behaviour of our model
with our own as well as published experimental data and
have found supporting evidence for our predictions in the
scientific literature. We therefore believe that our model is
a good representation of the EGF activated ERK pathway
which can be expanded and applied in the future to fur-
ther investigate the dynamics and functioning of growth
factor receptor signalling.
Authors' contributions
RJO carried out the modelling and analysis work, with ini-
tial investigations into cancerous mutation done by MEA.
AG and OS carried out the experimental laboratory work.
All of the work was supervised by DRG and WK. This work
was carried out whilst RJO, MEA, AG, OES and DRG were
working at the Bioinformatics Research Centre, Depart-
ment of Computing Science, University of Glasgow.
Additional material
Acknowledgements
This work was funded by the Department of Trade and Industry (DTI), 
under their Bioscience Beacon project programme. AG was funded by an 
industrial PhD studentship from Scottish Enterprise and Cyclacel.
References
1. Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, Kolch W:
Computational modelling of the receptor-tyrosine-kinase-
activated MAPK pathway.  Biochem J 2005, 392(Pt 2):249-261.
2. Yoon S, Seger R: The extracellular signal-regulated kinase:
multiple substrates regulate diverse cellular functions.
Growth Factors 2006, 24(1):21-44.
3. Langlois WJ, Sasaoka T, Saltiel AR, Olefsky JM: Negative feedback
regulation and desensitization of insulin- and epidermal
growth factor-stimulated p21ras activation.  J Biol Chem 1995,
270(43):25320-25323.
4. Waters SB, Holt KH, Ross SE, Syu LJ, Guan KL, Saltiel AR, Koretzky
GA, Pessin JE: Desensitization of Ras activation by a feedback
disassociation of the SOS-Grb2 complex.  J Biol Chem 1995,
270(36):20883-20886.
5. Dong C, Waters SB, Holt KH, Pessin JE: SOS phosphorylation and
disassociation of the Grb2-SOS complex by the ERK and JNK
signaling pathways.  J Biol Chem 1996, 271(11):6328-6332.
6. Corbalan-Garcia S, Yang SS, Degenhardt KR, Bar-Sagi D: Identifica-
tion of the mitogen-activated protein kinase phosphoryla-
tion sites on human Sos1 that regulate interaction with
Grb2.  Mol Cell Biol 1996, 16(10):5674-5682.
7. Douville E, Downward J: EGF induced SOS phosphorylation in
PC12 cells involves P90 RSK-2.  Oncogene 1997, 15(4):373-383.
8. Traverse S, Gomez N, Paterson H, Marshall C, Cohen P: Sustained
activation of the mitogen-activated protein (MAP) kinase
cascade may be required for differentiation of PC12 cells.
Comparison of the effects of nerve growth factor and epider-
mal growth factor.  Biochem J 1992, 288(Pt 2):351-355.
9. Kao S, Jaiswal RK, Kolch W, Landreth GE: Identification of the
mechanisms regulating the differential activation of the
mapk cascade by epidermal growth factor and nerve growth
factor in PC12 cells.  J Biol Chem 2001, 276(21):18169-18177.
10. Traverse S, Seedorf K, Paterson H, Marshall CJ, Cohen P, Ullrich A:
EGF triggers neuronal differentiation of PC12 cells that
overexpress the EGF receptor.  Curr Biol 1994, 4(8):694-701.
11. Brightman FA, Fell DA: Differential feedback regulation of the
MAPK cascade underlies the quantitative differences in EGF
and NGF signalling in PC12 cells.  FEBS Lett 2000,
482(3):169-174.
12. Santos SD, Verveer PJ, Bastiaens PI: Growth factor-induced
MAPK network topology shapes Erk response determining
PC-12 cell fate.  Nat Cell Biol 2007, 9(3):324-330.
13. Bos JL: ras oncogenes in human cancer: a review.  Cancer Res
1989, 49(17):4682-4689.
14. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J,
Woffendin H, Garnett MJ, Bottomley W, et al.: Mutations of the
BRAF gene in human cancer.  Nature 2002, 417(6892):949-954.
15. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS: Epider-
mal growth factor receptor (EGFR) and EGFR mutations,
function and possible role in clinical trials.  Ann Oncol 1997,
8(12):1197-1206.
16. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN,
Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD: Anti-
synthetic peptide antibody reacting at the fusion junction of
deletion-mutant epidermal growth factor receptors in
Additional file 1
EGF Model. This is an SBML file of our newly developed EGF model
Click here for file
[http://www.biomedcentral.com/content/supplementary/1752-
0509-3-100-S1.XML]
Additional file 2
Additional Information and Figures. This word file contains additional 
information such as laboratory protocols, details on how all the model 
knockouts were performed, model sensitivity analysis results, and addi-
tional figures.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1752-
0509-3-100-S2.DOC]
Additional file 3
Model Parameters. This excel file contains the values and sources of all 
the model parameters - specie initial concentrations and rate constants.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1752-
0509-3-100-S3.XLS]Page 16 of 17
(page number not for citation purposes)
BMC Systems Biology 2009, 3:100 http://www.biomedcentral.com/1752-0509/3/100Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
human glioblastoma.  Proc Natl Acad Sci USA 1990,
87(11):4207-4211.
17. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN,
McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al.: Mono-
clonal antibodies against EGFRvIII are tumor specific and
react with breast and lung carcinomas and malignant glio-
mas.  Cancer Res 1995, 55(14):3140-3148.
18. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn
G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ: Frequent expres-
sion of a mutant epidermal growth factor receptor in multi-
ple human tumors.  Cancer Res 1995, 55(23):5536-5539.
19. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang
CM, Gill GN, Wiley HS, Cavenee WK: The enhanced tumori-
genic activity of a mutant epidermal growth factor receptor
common in human cancers is mediated by threshold levels of
constitutive tyrosine phosphorylation and unattenuated sig-
naling.  J Biol Chem 1997, 272(5):2927-2935.
20. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman
HS, Bigner DD: Characterization of the epidermal growth fac-
tor receptor in human glioma cell lines and xenografts.  Can-
cer Res 1990, 50(24):8017-8022.
21. Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH,
Bigner DD, Bigner SH: Amplification and expression of the epi-
dermal growth factor receptor gene in human glioma
xenografts.  Cancer Res 1988, 48(8):2231-2238.
22. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whit-
tle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification,
enhanced expression and possible rearrangement of EGF
receptor gene in primary human brain tumours of glial ori-
gin.  Nature 1985, 313(5998):144-147.
23. Xu YH, Richert N, Ito S, Merlino GT, Pastan I: Characterization of
epidermal growth factor receptor gene expression in malig-
nant and normal human cell lines.  Proc Natl Acad Sci USA 1984,
81(23):7308-7312.
24. Schmidt MH, Furnari FB, Cavenee WK, Bogler O: Epidermal
growth factor receptor signaling intensity determines intra-
cellular protein interactions, ubiquitination, and internaliza-
tion.  Proc Natl Acad Sci USA 2003, 100(11):6505-6510.
25. Huang CY, Ferrell JE Jr: Ultrasensitivity in the mitogen-acti-
vated protein kinase cascade.  Proc Natl Acad Sci USA 1996,
93(19):10078-10083.
26. Burack WR, Sturgill TW: The activating dual phosphorylation of
MAPK by MEK is nonprocessive.  Biochemistry 1997,
36(20):5929-5933.
27. Ferrell JE Jr, Bhatt RR: Mechanistic studies of the dual phospho-
rylation of mitogen-activated protein kinase.  J Biol Chem 1997,
272(30):19008-19016.
28. Schoeberl B, Eichler-Jonsson C, Gilles ED, Muller G: Computa-
tional modeling of the dynamics of the MAP kinase cascade
activated by surface and internalized EGF receptors.  Nat Bio-
technol 2002, 20(4):370-375.
29. Brown KS, Hill CC, Calero GA, Myers CR, Lee KH, Sethna JP, Ceri-
one RA: The statistical mechanics of complex signaling net-
works: nerve growth factor signaling.  Physical Biology 2004,
1:184-195.
30. Sasagawa S, Ozaki Y, Fujita K, Kuroda S: Prediction and validation
of the distinct dynamics of transient and sustained ERK acti-
vation.  Nat Cell Biol 2005, 7(4):365-373.
31. Le Novere N, Bornstein B, Broicher A, Courtot M, Donizelli M,
Dharuri H, Li L, Sauro H, Schilstra M, Shapiro B, et al.: BioModels
Database: a free, centralized database of curated, published,
quantitative kinetic models of biochemical and cellular sys-
tems.  Nucleic Acids Res 2006:D689-691.
32. Hoops S, Sahle S, Gauges R, Lee C, Pahle J, Simus N, Singhal M, Xu L,
Mendes P, Kummer U: COPASI--a COmplex PAthway SImula-
tor.  Bioinformatics 2006, 22(24):3067-3074.
33. Orton RJ, Sturm OE, Gormand A, Wolch W, Gilbert DR: Compu-
tational modelling reveals feedback redundancy within the
epidermal growth factor receptor/extracellular-signal regu-
lated kinase signalling pathway.  IET Syst Biol 2008, 2(4):173-183.
34. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin
AP, Bornstein BJ, Bray D, Cornish-Bowden A, et al.: The systems
biology markup language (SBML): a medium for representa-
tion and exchange of biochemical network models.  Bioinfor-
matics 2003, 19(4):524-531.
35. Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT, Tsai SF, Huang
SF: Distinctive activation patterns in constitutively active and
gefitinib-sensitive EGFR mutants.  Oncogene 2006,
25(8):1205-1215.
36. Gao L, Feng Y, Bowers R, Becker-Hapak M, Gardner J, Council L,
Linette G, Zhao H, Cornelius LA: Ras-associated protein-1 regu-
lates extracellular signal-regulated kinase activation and
migration in melanoma cells: two processes important to
melanoma tumorigenesis and metastasis.  Cancer Res 2006,
66(16):7880-7888.
37. De Falco V, Castellone MD, De Vita G, Cirafici AM, Hershman JM,
Guerrero C, Fusco A, Melillo RM, Santoro M: RET/papillary thy-
roid carcinoma oncogenic signaling through the Rap1 small
GTPase.  Cancer Res 2007, 67(1):381-390.
38. Kholodenko BN, Demin OV, Moehren G, Hoek JB: Quantification
of short term signaling by the epidermal growth factor
receptor.  J Biol Chem 1999, 274(42):30169-30181.
39. Pinney J, Westhead D, McConkey G: Petri Net representations in
systems biology.  Biochemical Society Transactions 2003,
31:1513-1515.
40. Oliveira JS, Jones-Oliveira JB, Dixon DA, Bailey CG, Gull DW:
Hyperdigraph-theoretic analysis of the EGFR signaling net-
work: initial steps leading to GTP:Ras complex formation.  J
Comput Biol 2004, 11(5):812-842.
41. Chabrier N, Fages F: Symbolic model checking of biochemical
networks.  Lecture Notes in Computer Science 2003, 2602:149-162.
42. Calder M, Gilmore S, Hillston J: Modelling the influence of RKIP
on the ERK signalling pathway using the stochastic process
algebra PEPA.  Proceedings of Bio-Concur 2004, 1:36-49.
43. York RD, Yao H, Dillon T, Ellig CL, Eckert SP, McCleskey EW, Stork
PJ: Rap1 mediates sustained MAP kinase activation induced
by nerve growth factor.  Nature 1998, 392(6676):622-626.
44. Box GEP, Draper NR: Empirical Model-Building and Response
Surfaces.  Wiley, New York; 1987. Page 17 of 17
(page number not for citation purposes)
